Products

Online Inquiry

Name*

Phone

Email*

Services or Products of Interest*

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

BSP II Antibody

INQUIRY

CAT. NO.: AMA-0533

Target Information
UniProt ID	P21815

Product Details
Size	100 µL
Reactivity	Human, Mouse, Rat
Storage	Store at -20°C. Do not aliquot the antibody.
Purification	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human BSP II protein. Antibodies are purified by protein A and peptide affinity chromatography.

Usage
Application	WB, IP
Product Usage Information Dilution	Western Blotting (1:1000); Immunoprecipitation (1:50)
MW (Target)	80 kDa

Background
Bone sialoprotein II (BSP II) exists as a secreted protein in extracellular matrix of the skeleton BSP II is part of the small integrin binding ligand N-linked glycoprotein (SIBLING) family and its role is crucial for cell to matrix adhesion as well as between two active protein complexes Flexible binding capacity of BSP II also allows it to rapidly associate with various proteins, calcium, and mineralized phases of developing bone BSP II plays a central role in the initiation of hydroxyapatite microcalcification of breast cancer cells that contributes to the pathogenesis of bone metastasis. Recent evidence suggests that the downregulation of BSP II may lead to the reduced formation of metastatic lesions and bone metastasis in a human breast cancer model.

Background

Bone sialoprotein II (BSP II) exists as a secreted protein in extracellular matrix of the skeleton BSP II is part of the small integrin binding ligand N-linked glycoprotein (SIBLING) family and its role is crucial for cell to matrix adhesion as well as between two active protein complexes Flexible binding capacity of BSP II also allows it to rapidly associate with various proteins, calcium, and mineralized phases of developing bone BSP II plays a central role in the initiation of hydroxyapatite microcalcification of breast cancer cells that contributes to the pathogenesis of bone metastasis. Recent evidence suggests that the downregulation of BSP II may lead to the reduced formation of metastatic lesions and bone metastasis in a human breast cancer model.

Our customers have direct access to our experts and give timely feedback to any online inquiries. If you are interested in our products, please contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.